Vaccines (Development)

License Received To Market Comvax for Hib and Hepatitis B

Published in Hepatitis Weekly, October 21st, 1996

Comvax (Haemophilus b conjugate (meningococcal protein conjugate) and Hepatitis B (recombinant) vaccine) has been licensed by the U.S. Food and Drug Administration (FDA).

Comvax is developed by Merck & Co., Inc., West Point, Pennsylvania. It is indicated for vaccination of infants beginning at two months of age against both invasive Haemophilus influenzae type b diseases (Hib), which include meningitis, and hepatitis B virus, an important cause of viral hepatitis.

Comvax combines liquid PedvaxHIB (haemophilus b conjugate vaccine (meningococcal protein conjugate)) and Recombivax HBO (hepatitis B vaccine, (recombinant)), both vaccines currently...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1996-10-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry